Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|AHEP0731||COG||Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782; NSC#683864) Added to High Risk Stratum Treatment: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|AHOD03P1||COG||Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD): A Groupwide Pilot Study||Pediatric CIRB||Available to Open|
|AREN0321||COG||Treatment of High Risk Renal Tumors: A Groupwide Phase II Study||Pediatric CIRB||Completed|
|AREN1921||COG||Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)||Pediatric CIRB||Available to Open|
|AREN0533||COG||Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|AALL0932||COG||Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)||Pediatric CIRB||Available to Open|
|GOG-0201||GOG||Treatment of Patients with Stage IB2 Carcinoma of the Cervix: A Randomized Comparison of Radical Hysterectomy and Tailored Chemoradiation VERSUS Primary Chemoradiation||Adult CIRB - Late Phase Emphasis||Completed|
|AGCT0521||COG||Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors with Paclitaxel; Ifosfamide and Carboplatin: A Groupwide Phase II Study||Pediatric CIRB||Completed|
|URCC-16070||NCORP-University of Rochester Cancer Center||Treatment of Refractory Nausea||Cancer Prevention and Control CIRB||Available to Open|
|ARET0331||COG||Trial of Systemic Neoadjuvant Chemotherapy for Group B Intraocular Retinoblastoma: A Phase III Limited Institution Study||Pediatric CIRB||Completed|